CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Darifenacin hydrobromide

Last Updated: April 26, 2006
Result type: Reports
Project Number: SR0061-000
Product Line: Reimbursement Review

Generic Name: Darifenacin hydrobromide

Brand Name: Enablex

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Therapeutic Area: Bladder, overactive

Indications: Bladder, overactive

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 19, 2006

Recommendation Type: Do not list